Author

S. S. Skanland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:flow cytometry· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. J. Arribas· 1 shared A. K. Hilli· 1 shared A. R. Mato· 1 shared A. Repetto· 1 shared A. Urban· 1 shared E. Fiorito· 1 shared E. Normant· 1 shared F. Bertoni· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Arribas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 12, 2023

NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL

R. Generaloc, E. Fiorito, S. Foss…·J. Dahle

This paper develops NNV024, a humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life, showing improved efficacy against NHL and CLL cells compared to existing therapies.

DOI 10.1101/2023.07.12.548667

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 14, 2022

Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia

Y. Yin, P. Athanasiadis, L. Karlsen…·S. S. Skanland

This study uses ex vivo drug sensitivity testing to identify treatment responses and vulnerabilities in chronic lymphocytic leukemia patients, showing that pan-PI3Ki and combinations with venetoclax can be effective in idelalisib-refractory/intolerant cases.

DOI 10.1101/2022.04.14.488428

humanflow cytometry

𝕏 PostBluesky